CD9 and neoplasm: In contrast to CD9-CD38/αCD3-αEGFR Exos, the bone-retained BP-αCD3-αEGFR-ARC Exos are likely to undergo reduced clearances, promoting recruitments of cytotoxic T cells and subsequent tumor infiltration.